Investigational drug · Phase 3
LHRH
Also called: Luteinizing hormone-releasing hormone agonist, Luteinizing Hormone-Releasing Hormone Agonists
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for ER-Positive HER2-Negative Breast Cancer, Ovarian Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
1,148
Any phase or sponsor naming "LHRH"
First trial start
2021
Jan 28, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LHRH", any sponsor or status.
Conditions studied
As listed on its trial records.
- ER-Positive HER2-Negative Breast Cancer
- Ovarian Cancer
Approved drugs for the same conditions: Breast cancer · Ovarian cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "LHRH" as an intervention, largest first.
Brigham and Women's HospitalAcademic, hospital or other
NCT04897958 · 14,417 participants · Start Sep 21, 2019 · Primary completion Aug 1, 2021
Drug: Degarelix; Leuprolide · For: Prostate Cancer
Sites: Boston, Massachusetts
TakedaTakeda (TAK)
NCT02167893 · 11,288 participants · Start Oct 2005 · Primary completion Dec 2010
Drug: Leuprorelin acetate · For: Prostate Cancer
- Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast CancerPivotal-lookingCompleted
Institute of Cancer Research, United KingdomAcademic, hospital or other
NCT00002582 · 6,000 participants (planned) · Start Jun 1993
Drug: CMF regimen; cyclophosphamide and 6 more · For: Breast Cancer
Sites: Birmingham, United Kingdom; Glasgow, United Kingdom
IVFarma LLCIndustry
NCT04854707 · 5,484 participants · Start Jan 12, 2020 · Primary completion Dec 20, 2020
Drug: Follitropin Alfa; Follicle Stimulating Hormone/Luteinizing Hormone and 3 more · For: Reproductive Issues; Reproductive Disorder; Fertility Disorders and 3 more
Sites: Barnaul, Russia; Irkutsk, Russia; Kazan', Russia · 35 sites in all
Taipei Veterans General Hospital, TaiwanGovernment (non-federal)
NCT03778359 · 5,000 participants · Start Jan 1, 2005 · Primary completion Dec 31, 2015
Drug: Leuprorelin; Dienogest and 1 more · For: Endometriosis; Adenomyosis
Sites: Taipei County, Taiwan
- RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local SurgeryPivotal-lookingCompleted
University College, LondonAcademic, hospital or other
NCT00541047 · 4,236 participants · Start Nov 2007 · Primary completion Jul 27, 2022
Drug: bicalutamide; goserelin acetate and 1 more · For: Gastrointestinal Complications; Prostate Cancer; Sexual Dysfunction and 1 more
Sites: Kelowna, Canada; Vancouver, Canada; London, Canada · 58 sites in all
- A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04961996 · 4,170 participants · Start Aug 27, 2021 · Primary completion Aug 8, 2025
Drug: Giredestrant; Physician's Choice of Endocrine Therapy and 1 more · For: Early Breast Cancer
Sites: Daphne, Alabama; Bakersfield, California; Fullerton, California · 621 sites in all
NRG OncologyAcademic, hospital or other
NCT05879926 · 3,960 participants (planned) · Start Oct 18, 2023 · Primary completion Jan 2032
Drug: Ovarian Function Suppression + Aromatase Inhibitor; Adjuvant Chemotherapy + Ovarian Function Suppression · For: Breast Cancer
Sites: Birmingham, Alabama; Anchorage, Alaska; Fairbanks, Alaska · 1,276 sites in all
- A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate CancerPivotal-lookingRecruiting
University College, LondonAcademic, hospital or other
NCT06320067 · 3,360 participants (planned) · Start Jun 11, 2024 · Primary completion Apr 2031
Drug: Androgen Deprivation Therapy (ADT); Androgen Receptor Signalling Inhibitor (ARPI) and 1 more · For: Prostate Cancer Metastatic
Sites: Barnsley, United Kingdom; Cambridge, United Kingdom; Exeter, United Kingdom · 18 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT06830720 · 3,250 participants (planned) · Start Feb 20, 2025 · Primary completion Jun 30, 2030
Drug: ribociclib + AI ± LHRH; abemaciclib + ET ± LHRH and 1 more · For: Breast Neoplasms
Sites: Wiener Neustadt, Austria; Innsbruck, Austria; Linz, Austria · 287 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Thermosensitive and tumor-targeted asparaginase fusion protein enables metabolic-immunotherapy for solid tumors.
Gong L, Wang X, Zheng Y, et al. · Biomaterials 2027
- Leuprorelin Acetate for Spinal and Bulbar Muscular Atrophy: A Systematic Review of Clinical Efficacy, Long-Term Outcomes, and Safety Considerations.
Wang B, Wang I, Park C, et al. · Muscle Nerve 2026
- H&E to recurrence score: A step forward, but not yet a substitute for genomic testing.
Zhou S, Ke Q · Transl Oncol 2026
- Transdermal estradiol for prostate cancer: how do patients compare it to other options for androgen deprivation therapy?
Sears C, Wassersug R, Brown E, et al. · Can J Urol 2026
- Comparison of cardiovascular events in patients with metastatic hormone sensitive prostate cancer treated with LHRH agonists to LHRH antagonists in the US: A retrospective cohort study.
Titus RS, Velasquez EL, Mundra V, et al. · Urol Oncol 2026
- Artificial propagation, embryonic development and early larval growth of Triplophysa strauchii.
Hao Y, Wang Z, Chen Y, et al. · J Fish Biol 2026
Also in development for ER-Positive HER2-Negative Breast Cancer
- RYZ101Phase 32 trials
RayzeBio, Inc. · Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.